Early treatment for COVID-19 is available at the Monoclonal Antibody Regional Centers (MARC)

What are Monoclonal Antibodies?

Monoclonal antibodies are proteins made in a lab that help boost the immune system to fight viruses. The monoclonal antibody combination treatments of bamlanivimab plus etesevimab from Eli Lilly and casirivimab plus imdevimab from Regeneron have been authorized for emergency use by FDA to treat mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg / 88 lbs.) with positive results of direct SARS-CoV-2 (the virus that causes COVID-19) viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. They have been shown in clinical trials (bamlanivimab/etesevimab | casirivimab/imdevimab) to reduce COVID-19-related hospitalization and emergency room visits.

Who Qualifies?

  • Medically eligible (bamlanivimab/etesevimab | casirivimab/imdevimab), symptomatic COVID-19 positive patients whose COVID-19 symptoms have developed within the last 10 days
  • Treatment will be provided at no cost to all medically eligible individuals who live or work in California, regardless of health insurance or immigration status


  • Health Providers
  • Patients


Additional Resources

Questions? Email  COVIDtreatment@sdcounty.ca.gov